News | March 18, 2014

Plaques in Brain Scans Forecast Cognitive Impairment

March 18, 2014 — Brain imaging using nuclear imaging radiotracers can detect early evidence of Alzheimer's disease that may predict future cognitive decline among adults with mild or no cognitive impairment. This is according to a 36-month follow-up study led by Duke Medicine.

The national, multicenter study confirms earlier findings suggesting that identifying silent beta-amyloid plaque build-up in the brain could help guide care and treatment decisions for patients at risk for Alzheimer's. The findings appeared online March 11, 2014, in Molecular Psychiatry, a Nature Publishing Group journal.

"Our research found that healthy adults and those with mild memory loss who have a positive scan for these plaques have a much faster rate of decline on memory, language and reasoning over three years," said lead author P. Murali Doraiswamy, M.D., professor of psychiatry and director of the neurocognitive disorders program at Duke.

Alzheimer's disease – which currently has no cure – afflicts an estimated five million U.S. adults, and is the sixth-leading cause of death among adults, according to the Centers for Disease Control and Prevention. Prior studies have found that changes in the brain begin years, and possibly decades, before cognitive symptoms emerge.

A biomarker that could accurately identify those at greatest risk for cognitive decline could help clinicians better evaluate and treat patients, while also accelerating the testing of drugs to treat the disease.

The current study, which enrolled 152 adults ages 50 and older, was designed to assess whether silent pathological changes in the brain associated with Alzheimer's and detected with positron emission tomography (PET) can predict cognitive decline. Of the participants, 69 had normal cognitive function at the start of the study, 52 had been recently diagnosed with mild cognitive impairment, and 31 were diagnosed with Alzheimer's disease.

Subjects completed cognitive tests and underwent PET scans of their brains. This type of imaging uses a radioactive tracer to look for chemical signs of disease in specific tissues.

The radioactive dye used, florbetapir (Amyvid), was approved by the U.S. Food and Drug Administration (FDA) in 2012 for PET imaging of the brain to estimate beta-amyloid plaque density in patients being evaluated for cognitive impairment. It binds to the beta-amyloid plaques that characterize Alzheimer's disease, helping to measure the extent to which plaques have formed in different brain regions. Using this information, the researchers rated the PET scans as positive or negative.

After 36 months, the researchers repeated the same cognitive exams to reassess participants. They found that those with mild or no cognitive impairment who had evidence of plaques at the trial's start worsened to a greater degree on cognitive tests than those with negative scans.

Thirty-five percent of plaque-positive participants who started with mild cognitive impairment progressed to Alzheimer's, compared to 10 percent without plaque. In addition, plaque-positive participants with mild impairment were more than twice as likely to be started on cognitive-enhancing medication than those without plaque.

Conversely, those with negative scans experienced much less decline: 90 percent of participants with mild cognitive impairment but no plaque did not progress to Alzheimer's. This finding supports the negative predictive value of using PET imaging to identify patients unlikely to decline, which has important implications for both clinical research and treatment.

"Having a negative scan could reassure people that they are not likely to be at risk for progression in the near future," Doraiswamy said.

Doraiswamy cautioned that florbetapir is currently not approved to predict the development of dementia and is not used as a screening tool in cognitively normal people. Future longitudinal studies are needed to further clarify the prognostic role of beta-amyloid plaque PET imaging in a clinical setting.

"Even though our study suggests the test has predictive value in normal adults, we still need additional evidence," Doraiswamy said. "We need longer-term studies to look at the consequences of silent brain plaque build-up, given that it affects 15 to 30 percent of normal older people."

Doraiswamy added that the findings provide support for planned and ongoing multicenter clinical trials of asymptomatic older adults with plaque-positive scans. The research also has implications for other conditions where amyloid might play a role, such as traumatic brain injury.

For more information: www.nature.com/mp

Related Content

Smartphone Addiction Creates Imbalance in Brain
News | Mobile Devices | January 11, 2018
Researchers have found an imbalance in the brain chemistry of young people addicted to smartphones and the internet,...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Neurofeedback Shows Promise in Treating Tinnitus

The standard approach to fMRI neurofeedback. Image courtesy of Matthew Sherwood, Ph.D.

News | Magnetic Resonance Imaging (MRI) | January 11, 2018
January 11, 2018 — Researchers using...
New Studies Show Brain Impact of Youth Football
News | Neuro Imaging | January 09, 2018
School-age football players with a history of concussion and high impact exposure undergo brain changes after one...
WEBINAR: Neuroimaging from a Clinical MRI Perspective, sponsored by Philips Healthcare. How to better manage your MRI department.
Webinar | Magnetic Resonance Imaging (MRI) | January 08, 2018
The CME credit webinar "Neuroimaging from a Clinical MRI Perspective," will explain how imaging departments can becom
MRI Shows Brain Differences Among ADHD Patients
News | Neuro Imaging | January 02, 2018
Information from brain magnetic resonance images (MRIs) can help identify people with attention deficit hyperactivity...
Migraines Linked to High Sodium Levels in Cerebrospinal Fluid
News | Neuro Imaging | December 29, 2017
Migraine sufferers have significantly higher sodium concentrations in their cerebrospinal fluid than people without the...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
MRI Uncovers Brain Abnormalities in People With Depression and Anxiety

Significant cortical thickness differences among the three groups. All regions survived clusterwise-correction (p<0.001). Image courtesy of Youjin Zhao.

News | Neuro Imaging | December 22, 2017
Researchers using magnetic resonance imaging (MRI) have discovered a common pattern of structural abnormalities in the...
Videos | Neuro Imaging | December 21, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Overlay Init